## ΔVΔNOS | MICROCUFF\* Endotracheal Tubes

# IS YOUR CUFF DOING THE JOB?

Polyurethane cuff and subglottic secretion drainage help prevent early- and late-onset VAP<sup>1</sup>

## LEADING AUTHORITIES: SUBGLOTTIC SUCTIONING IS A BEST PRACTICE



## AMERICAN THORACIC SOCIETY INFECTIOUS DISEASES SOCIETY OF AMERICA

"Continuous aspiration of subglottic secretions can reduce the risk of early-onset VAP, and should be used, if available<sup>2</sup>."

## THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA

"[Providing ET] with subglottic secretion drainage ports for patients expected to require greater than 48 or 72 hours of mechanical ventilation.

Considered "basic practice" for preventing ventilator-associated pneumonia in adult patients<sup>3</sup>."

## AMERICAN ASSOCIATION OF CRITICAL-CARE NURSES

"Use an endotracheal tube (ET) with a dorsal lumen above the endotracheal cuff to allow drainage by continuous suctioning of tracheal secretions that accumulate in the subglottic area<sup>4</sup>."

## **CENTERS FOR DISEASE CONTROL (CDC)**

"...use an endotracheal tube with a dorsal lumen above the endotracheal cuff to allow drainage (by continuous or frequent intermittent suctioning) of tracheal secretions that accumulate in the patient's subglottic area<sup>5</sup>."

## RECOMMENDATION OF THE COMMISSION FOR HOSPITAL HYGIENE AND INFECTION PREVENTION (KRINKO) AT THE ROBERT KOCH INSTITUTE

"The use of a subglottic suctioning endotracheal tube to prevent pneumonia in patients who require ventilation for more than 72 hours (Cat. IA). The risk of pneumonia from reintubating the patient should be weighed against the benefits of achieving a subglottic secretion drainage by replacing a regular endotracheal tube with an endotracheal tube with subglottic suctioning. To date, no evidence has yet been provided for the type of secretion drainage - intermittent or continous - and the preventive benefit of tubes with polyurethane cuff / newly designed cuff geometry (Cat. III)<sup>6</sup>."

## UK DEPARTMENT OF HEALTH

"The use of tracheal tubes with subglottic drainage ports can reduce VAP by preventing contaminated oral secretions that accumulate above the tracheal cuff intubated patients leaking past the cuff into the lungs."

"A tracheal tube (endotracheal or tracheostomy) which has a subglottic secretion drainage port is used if the patient is expected to be intubated for >72 hrs<sup>7</sup>."

## POLYURETHANE CUFF MATERIAL: BETTER FIT & BETTER SEAL

### THE AVANOS<sup>\*</sup> MICROCUFF<sup>\*</sup> TUBE FEATURES AN ADVANCED MICROTHIN POLYURETHANE CUFF MATERIAL

- Provides an effective seal at low cuff pressure
- May reduce micro-aspiration of potentially infectious pharyngeal secretions<sup>14</sup> – Potentially lowers risk of VAP in prolonged ventilation<sup>1</sup>

"Polyurethane cuffs offered superior seal to PVC cuffs regardless of shape, adequate seal was maintained through 24 h." Rihard Knafelj. Critical Care, 2016.<sup>15</sup>


- Designed for better contact with tracheal contour<sup>14</sup>
- Thinner material allows for greater visualisation of vocal cords when cuff is deflated

"Significantly less fluid leakage was observed among PU-cuffed tubes than in PVC-cuffed tubes, regardless of PEEP or suctioning settings."

Stijn I. Blot, et al. Critical Care, 2016.16

#### Polyurethane can be made thinner and still maintain its strength<sup>17</sup>


- Polyurethane (13 microns) cuff membranes used in the MICROCUFF<sup>\*</sup> tubes are subtantially thinner than conventional PVC cuffs (50-80 microns<sup>13</sup>)
- Puncture strength of MICROCUFF\* cuff is almost double compared to conventional PVC cuffs<sup>17</sup>
- Burst pressure of MICROCUFF<sup>\*</sup> tube is more than double compared to conventional PVC cuffs<sup>17</sup>



## MICROCUFF<sup>\*</sup> SUBGLOTTIC SUCTIONING ENDOTRACHEAL TUBES

#### Demonstrated difference:

An independent laboratory, Clinimark, conducted a study to measure the subglottic suctioning efficacy of PVC-cuffed endotracheal tubes compared to polyurethane-cuffed endotracheal tubes<sup>18</sup>.



## MICROCUFF<sup>\*</sup> & MICROCUFF<sup>\*</sup> SUBGLOTTIC SUCTIONING ENDOTRACHEAL TUBES<sup>19</sup>

	AVANOS <sup>®</sup> MICROCUFF <sup>®</sup> ENDOTRACHEAL TUBES	COMPETITOR ENDOTRACHEAL TUBES
Tube material	PVC firm, does not kink when at body temperature	Soft
DEHP free	Yes	No or not mentioned
Murphy eye	Yes	Yes
Shape of cuff	Cylindrical with maximum tracheal contact	Taper or pear shape
Cuff material	PU (ultra thin <13 microns)	PVC or PU (>15 microns)
Position of the cuff on the tube	Distal (to fit any trachea)	Higher/proximal
Cuff volume / cuff pressure	Larger volume to adapt to any size shape of trachea (typically need 12 cc syringe)	Lower
Suction valve + flush port	Yes	No
Saline rinsing FDA approved	Yes	No
Closed system when instilling air or saline	Yes	No
Sizes	7 to 9 mm MICROCUFF <sup>*</sup> Subglottic ET / 5 to 10 mm MICROCUFF <sup>*</sup> ET	6 to 10 mm

## VENTILATOR-ASSOCIATED PNEUMONIA

### VAP IS A MAJOR CLINICAL CONCERN ASSOCIATED WITH HIGH INCIDENCE RATES, MORTALITY AND COSTS<sup>8</sup>

It's worth taking measures to prevent even one case of VAP.

- Approximately **86%** of hospital-associated pneumonia is linked with mechanical ventilation<sup>9</sup>
- VAP may account for up to **60%** of all deaths due to Healthcare-Associated Infections (HAIs)<sup>8</sup>
- Approximately 8-28% of patients on ventilation develop VAP<sup>10</sup>
- Hospital-associated pneumonia patients have a mortality rate of 20% to 41%<sup>11</sup>
- VAP increases patient time in the ICU by 4 to 6 days<sup>12</sup>
- Each incidence of VAP has been estimated to generate an increased mean cost of more than 37 000€ (more than £31 000)<sup>12</sup>

### MICRO-ASPIRATION IS A MAJOR CAUSE OF VAP<sup>10</sup>

- Micro-aspiration of potentially infectious secretions through gaps in the endotracheal tube cuff is known to be a leading cause of VAP<sup>10</sup>
- The cuff seal is the final barrier that protects the lungs from aspiration of potentially infectious pharyngeal secretions<sup>13</sup>



### MICROCUFF<sup>\*</sup> & MICROCUFF<sup>\*</sup> SUBGLOTTIC SUCTIONING ENDOTRACHEAL TUBES

CODE	TUBE SIZE I.D.	PACKAGING	
35210	5.0 mm	1 case - 10/dispenser	—
35211	5.5 mm	1 case - 10/dispenser	
35212	6.0 mm	1 case - 10/dispenser	
35213	6.5 mm	1 case - 10/dispenser	
35214	7.0 mm	1 case - 10/dispenser	
35215	7.5 mm	1 case - 10/dispenser	
35216	8.0 mm	1 case - 10/dispenser	
35217	8.5 mm	1 case - 10/dispenser	all man and and
35218	9.0 mm	1 case - 10/dispenser	
35220	10.0 mm	1 case - 10/dispenser	

#### AVANOS\* MICROCUFF\* endotracheal tubes, oral / nasal magill, murphy eye

#### AVANOS<sup>\*</sup> MICROCUFF<sup>\*</sup> subglottic suctioning endotracheal tubes

CODE	TUBE SIZE I.D.	PACKAGING
13220	7.0 mm	1 case - 10/dispenser
13221	7.5 mm	1 case - 10/dispenser
13222	8.0 mm	1 case - 10/dispenser
13223	8.5 mm	1 case - 10/dispenser
13224	9.0 mm	1 case - 10/dispenser



References 1. Lorente L, Lecuona M, Jimenez A, Mora ML, Sierra A, Influence of an Endotracheal Tube with Polyurethane Cuff and Subglottic Secretion Drainage on Pneumonia, May 2007. Am. J. Respir and Crit Care Med 176 (11): 1 Dec 2007. 2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the Management of Adults with Hospital-Acquired, Ventilator-Associated Aneumonia. An J Respir Crit Care Med. 2005;171(4):388-416;395. 3. The Society for Healthcare-Epidemiology of America. Practice Recommendation: Klompas M, Branson R, Eichenwald EC, Greene LR, Howell MD, Lee G, Magill SS, Maragakis LL, Priebe GP, Speck K, Yokoe DS, Berenholtz SM. Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals:2014 Update. Infection Control & Hospital Epidemiology, 35(8), pp 915-936. Aug 2014. doi:10.1086/527363. 4. AACN Practice Alert, Ventilator-Associated Pneumonia, 2003:Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 26 Mar2004;531-36, pi 4. 6. Commission for recommendation Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute. Prevention of nosocomial ventilator-associated Pneumonia. BMdsgesundheitsbl (2013) 56:1578-1590 T. UK Department of Health. High Impact Intervention (Cre Rudu Level Ventilated-Associated Pneumonia. http://hcai.dh.gov.uk/files/2011/03/2011-03-14-HI-Ventilator-Associated-Pneumonia. FNIAL.pdf 8. Kollef MH. What Is Ventilator-Associated Pneumonia and Why Is It Important? Respiratory Care. 2005 June; 50(6): 714-724. 9. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomia Infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999 May;27(5): 887-903. 11. Ventilator-Associated Pneumonia. Crit. Care Nates. 2008; 283-86. 12. Rello J, Ollendorf D, Oster G, Vera-Llonch M, Bellm L, et al. Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large SUS advases. Chest. 2002; 122:2115-2121. 13. D

Dr. Stijn I. Blot and Dr. Rihard Knafelj have a consulting/speaking financial relationship with Avanos Medical Inc. and/or one of its affiliates.



For more information, please send an email to customerservice.uk.ie@avanos.com

\* Registered Trademark or Trademark of Avanos Medical, Inc., or its affiliates. © 2019 AVNS. All rights reserved. HC609-01-UK